97 related articles for article (PubMed ID: 16438939)
21. Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.
Toma S; Yamashiro T; Arakaki S; Shiroma J; Maeshiro T; Hibiya K; Sakamoto N; Kinjo F; Tateyama M; Fujita J
J Viral Hepat; 2009 Jul; 16(7):506-12. PubMed ID: 19302339
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
Thomson JA; Perni RB
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
[TBL] [Abstract][Full Text] [Related]
23. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
[TBL] [Abstract][Full Text] [Related]
24. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
Chen CS; Chiou CT; Chen GS; Chen SC; Hu CY; Chi WK; Chu YD; Hwang LH; Chen PJ; Chen DS; Liaw SH; Chern JW
J Med Chem; 2009 May; 52(9):2716-23. PubMed ID: 19419203
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of new 2'-beta-C-methyl related triciribine analogues as anti-HCV agents.
Smith KL; Lai VC; Prigaro BJ; Ding Y; Gunic E; Girardet JL; Zhong W; Hong Z; Lang S; An H
Bioorg Med Chem Lett; 2004 Jul; 14(13):3517-20. PubMed ID: 15177464
[TBL] [Abstract][Full Text] [Related]
26. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
27. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system.
Hwang DR; Wu YS; Chang CW; Lien TW; Chen WC; Tan UK; Hsu JT; Hsieh HP
Bioorg Med Chem; 2006 Jan; 14(1):83-91. PubMed ID: 16140536
[TBL] [Abstract][Full Text] [Related]
29. The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
Smith DB; Kalayanov G; Sund C; Winqvist A; Pinho P; Maltseva T; Morisson V; Leveque V; Rajyaguru S; Le Pogam S; Najera I; Benkestock K; Zhou XX; Maag H; Cammack N; Martin JA; Swallow S; Johansson NG; Klumpp K; Smith M
J Med Chem; 2009 Jan; 52(1):219-23. PubMed ID: 19055482
[TBL] [Abstract][Full Text] [Related]
30. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
32. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
33. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
34. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
35. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of the NTPase/helicases of hepatitis C and related Flaviviridae viruses.
Bretner M; Najda A; Podwińska R; Baier A; Paruch K; Lipniacki A; Piasek A; Borowski P; Kulikowski T
Acta Pol Pharm; 2004 Dec; 61 Suppl():26-8. PubMed ID: 15909930
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibitors of hepatitis C virus replication.
Neyts J
Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
[TBL] [Abstract][Full Text] [Related]
38. The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.
McGuigan C; Perrone P; Madela K; Neyts J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4316-20. PubMed ID: 19523820
[TBL] [Abstract][Full Text] [Related]
39. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase.
Wang YK; Rigat KL; Roberts SB; Gao M
Anal Biochem; 2006 Dec; 359(1):106-11. PubMed ID: 17054898
[TBL] [Abstract][Full Text] [Related]
40. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
Xu J; Liu S; Xu Y; Tien P; Gao G
Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
